Skip to content
DataLookout
Menu

NCT04753879

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 20 versions: 14 with changes below, 6 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 4, 2026 Show 7 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 1 word
    • Trial completed
    • Primary completion date changed from estimate of Jul 1, 2026 to May 7, 2026
    • Enrollment target: estimated 38 to confirmed 36
    • Secondary endpoint revised
    • Collaborators: details revised at 1 of 1 entry
  2. Minor Primary and study completion dates moved earlier to Jul 1, 2026v19
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v18
  4. Notable Primary completion date: Dec 1, 2025 to Dec 1, 2026v17
  5. Minor Site contact updatedv16
Show 8 earlier versionsHide 8 earlier versions
  1. Minor Site contact updatedv11
  2. Minor Start date changed from estimate of Dec 2021 to Sep 29, 2021v9
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v8
  4. Notable Start date: Aug 2021 to Dec 2021
    • Primary completion date: Aug 1, 2025 to Dec 1, 2025
    • Study completion date: Feb 1, 2029 to Dec 1, 2029
    v7
  5. Notable Eligibility criteria expanded, about 11 wordsv6
  6. Minor Primary completion date: Aug 2025 to Aug 1, 2025
    • Study completion date: Aug 2025 to Feb 1, 2029
    v5
  7. Notable Start date: Apr 2021 to Aug 2021
    • Primary and study completion dates: Apr 2025 to Aug 2025
    v4
  8. Notable Primary endpoints: 1 to 2v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression-free Survival (PFS) Rate at 6 Months
Timeframe: 6 Months

Secondary (1)

Number of Participants Experiencing Grade 3 or Above Drug-related Toxicities

Arms and interventions

GAX-CI Chemotherapy with Pembrolizumab and OlaparibExperimental

The treatment period will consist of a chemotherapy phase with GAX-CI (gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan) followed by a maintenance phase with pembrolizumab and olaparib. The chemotherapy phase will consist of 6 cycles of GAX-CI. Post-GAX-CI treatment, patients will receive pembrolizumab and olaparib. Maintenance phase treatment may continue up to a maximum of 2 years. Patients who had stable disease or better post-GAX-CI treatment and develop clinical or radiographic progressive disease following initiation of maintenance therapy, or those who become intolerant of treatment with either pembrolizumab or olaparib, may be retreated with GAX-CI if the PI deems that the patient will derive meaningful clinical benefit.

Drugs: Nab-paclitaxel, Gemcitabine, Cisplatin, Irinotecan, Capecitabine, Pembrolizumab, Olaparib

Sites

1 site in 1 country

  • Sidney Kimmel Comprehensive Cancer CenterBaltimore, Maryland, United States